The cornerstone of all vaccine development efforts at Immunovaccine is the company’s DepoVax™ vaccine adjuvanting platform. DepoVax is a patented vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. The result is a strong, specific and sustained immune response with the capability for single-dose effectiveness.
Antigen + AdjuvantSuspend in Oil
The DepoVax platform possesses impressive flexibility, allowing it to work with a broad range of target antigens in various therapeutic applications. The technology is also commercially scalable, with potential for years of stability and ease of use in the clinic.
To date, DepoVax has served as the basis for Immunovaccine’s two clinical-stage cancer vaccines, as well as a number of partnered vaccine programs spanning infectious diseases, bio-terrorism, addiction medicine and animal health. These collaborators include many leaders in their respective areas of focus including the National Institutes of Health, Weill Cornell Medical College and Zoetis (formerly Pfizer Animal Health).
The graphic below illustrates DepoVax's ability to efficiently attract antigen presenting cells and allow for the controlled uptake of the antigen and adjuvant.
DepoVax Advantages & Applications
Fast, strong and long-lasting immune responses
Humoral and/or cellular response possible
Compatible with different antigens
Stable formulation: long-term storage at ambient temperatures if necessary
Easy to re-suspend and administer
DepoVax in Cancer:
Maintain remission and combat micro-metastases
Provides “polyfunctional” cellular response
Targets tumor cells, unhealthy cells
DepoVax in Infectious Disease:
Rapid and robust immune response sufficient for disease protection